Rational	O
use	O
of	O
rasburicase	B:C0937932
for	O
the	O
treatment	O
and	O
management	O
of	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Rational	O
use	O
of	O
rasburicase	O
for	O
the	O
treatment	B:C0087111
and	O
management	O
of	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Rational	O
use	O
of	O
rasburicase	O
for	O
the	O
treatment	O
and	O
management	B:C0376636
of	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Rational	O
use	O
of	O
rasburicase	O
for	O
the	O
treatment	O
and	O
management	O
of	O
tumor	B:C0041364
lysis	I:C0041364
syndrome	I:C0041364
.	O

There	O
is	O
a	O
lack	O
of	O
high	O
-	O
level	O
evidence	O
identifying	O
meaningful	O
outcomes	O
and	O
the	O
optimal	O
place	O
in	O
therapy	B:C0087111
of	O
rasburicase	O
in	O
patients	O
with	O
,	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

There	O
is	O
a	O
lack	O
of	O
high	O
-	O
level	O
evidence	O
identifying	O
meaningful	O
outcomes	O
and	O
the	O
optimal	O
place	O
in	O
therapy	O
of	O
rasburicase	B:C0937932
in	O
patients	O
with	O
,	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

There	O
is	O
a	O
lack	O
of	O
high	O
-	O
level	O
evidence	O
identifying	O
meaningful	O
outcomes	O
and	O
the	O
optimal	O
place	O
in	O
therapy	O
of	O
rasburicase	O
in	O
patients	O
with	O
,	O
or	O
at	B:C0332167
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

There	O
is	O
a	O
lack	O
of	O
high	O
-	O
level	O
evidence	O
identifying	O
meaningful	O
outcomes	O
and	O
the	O
optimal	O
place	O
in	O
therapy	O
of	O
rasburicase	O
in	O
patients	O
with	O
,	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	B:C0041364
lysis	I:C0041364
syndrome	I:C0041364
.	O

The	O
primary	O
objective	O
of	O
this	O
study	B:C2603343
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	O
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	O
care	I:C0344211
,	O
xanthine	O
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	B:C0220825
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	O
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	O
care	I:C0344211
,	O
xanthine	O
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	B:C0870077
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	O
care	I:C0344211
,	O
xanthine	O
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	O
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	B:C0344211
care	I:C0344211
,	O
xanthine	O
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	O
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	O
care	I:C0344211
,	O
xanthine	B:C0302609
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution	O
-	I:C0870077
specific	I:C0870077
guideline	I:C0870077
emphasizing	O
supportive	O
care	I:C0344211
,	O
xanthine	O
oxidase	I:C0302609
inhibitors	I:C0302609
,	O
and	O
lower	O
doses	O
of	O
rasburicase	B:C0937932
.	O

Methods	B:C0025663

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	B:C0459914
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	B:C0937932
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	B:C1708333
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	B:C0041364
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	B:C0162791
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	B:C0937932
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	B:C0376545
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	B:C1698088
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	I:C1698088
malignancies	I:C1698088
,	O
and	O
a	O
uric	B:C0202239
acid	I:C0202239
level	I:C0202239
between	O
8	O
and	O
15	O
mg	O
/	O
dL	O
.	O

The	O
primary	O
efficacy	O
outcome	O
assessed	O
the	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
achieving	O
a	O
uric	B:C0202239
acid	I:C0202239
level	I:C0202239
<	O
8	O
mg	O
/	O
dL	O
within	O
48	O
h	O
using	O
a	O
one	O
-	I:C0392366
sided	I:C0392366
noninferiority	I:C0392366
test	I:C0392366
.	O

The	O
primary	O
efficacy	O
outcome	O
assessed	O
the	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
achieving	O
a	O
uric	O
acid	I:C0202239
level	I:C0202239
<	O
8	O
mg	O
/	O
dL	O
within	O
48	O
h	O
using	O
a	O
one	B:C0392366
-	I:C0392366
sided	I:C0392366
noninferiority	I:C0392366
test	I:C0392366
.	O

The	O
principle	O
safety	O
outcomes	O
analyzed	B:C0936012
included	O
incidence	O
of	O
acute	O
kidney	I:C2609414
injury	I:C2609414
and	O
hemodialysis	O
requirement	O
.	O

The	O
principle	O
safety	O
outcomes	O
analyzed	O
included	O
incidence	O
of	O
acute	B:C2609414
kidney	I:C2609414
injury	I:C2609414
and	O
hemodialysis	O
requirement	O
.	O

The	O
principle	O
safety	O
outcomes	O
analyzed	O
included	O
incidence	O
of	O
acute	O
kidney	I:C2609414
injury	I:C2609414
and	O
hemodialysis	B:C0019004
requirement	O
.	O

One	O
hundred	O
sixty	O
-	O
one	O
patients	O
met	O
inclusion	O
criteria	O
and	O
were	O
included	O
in	O
the	O
study	B:C2603343
.	O

Within	O
48	O
h	O
of	O
an	O
elevated	B:C0041981
uric	I:C0041981
acid	I:C0041981
level	I:C0041981
,	O
treatment	O
was	O
successful	O
in	O
97.03	O
%	O
of	O
patients	O
in	O
the	O
conservative	O
group	O
,	O
as	O
compared	O
with	O
98.33	O
%	O
in	O
the	O
aggressive	O
group	O
(	O
difference	O
,	O
1.3	O
percentage	O
points	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-	O
3.33	O
to	O
5.93	O
)	O
.	O

Within	O
48	O
h	O
of	O
an	O
elevated	O
uric	I:C0041981
acid	I:C0041981
level	I:C0041981
,	O
treatment	O
was	O
successful	O
in	O
97.03	O
%	O
of	O
patients	O
in	O
the	O
conservative	B:C0459914
group	O
,	O
as	O
compared	O
with	O
98.33	O
%	O
in	O
the	O
aggressive	O
group	O
(	O
difference	O
,	O
1.3	O
percentage	O
points	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-	O
3.33	O
to	O
5.93	O
)	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
requiring	O
hemodialysis	B:C0019004
(	O
2.97	O
%	O
vs.	O
10.0	O
%	O
,	O
p-	O
value	O
0.079	O
)	O
,	O
or	O
incidence	O
of	O
acute	O
kidney	I:C2609414
injury	I:C2609414
(	O
4.0	O
%	O
vs.	O
12.5	O
%	O
,	O
p-	O
value	O
1.00	O
)	O
between	O
the	O
treatment	O
group	O
and	O
control	O
group	O
,	O
respectively	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
requiring	O
hemodialysis	O
(	O
2.97	O
%	O
vs.	O
10.0	O
%	O
,	O
p-	O
value	O
0.079	O
)	O
,	O
or	O
incidence	O
of	O
acute	B:C2609414
kidney	I:C2609414
injury	I:C2609414
(	O
4.0	O
%	O
vs.	O
12.5	O
%	O
,	O
p-	O
value	O
1.00	O
)	O
between	O
the	O
treatment	O
group	O
and	O
control	O
group	O
,	O
respectively	O
.	O

Conclusions	O
Conservative	B:C0459914
rasburicase	O
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	O
use	O
in	O
patients	O
with	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Conclusions	O
Conservative	O
rasburicase	B:C0937932
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	O
use	O
in	O
patients	O
with	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Conclusions	O
Conservative	O
rasburicase	O
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	B:C0937932
use	O
in	O
patients	O
with	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Conclusions	O
Conservative	O
rasburicase	O
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	O
use	O
in	O
patients	O
with	O
or	O
at	B:C0332167
high	I:C0332167
risk	I:C0332167
for	O
tumor	O
lysis	I:C0041364
syndrome	I:C0041364
.	O

Conclusions	O
Conservative	O
rasburicase	O
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	O
use	O
in	O
patients	O
with	O
or	O
at	O
high	I:C0332167
risk	I:C0332167
for	O
tumor	B:C0041364
lysis	I:C0041364
syndrome	I:C0041364
.	O

